If It Works, Don’t Touch It? A Cell-Based Approach to Studying 2-[<sup>18</sup>F]FDG Metabolism
The glucose derivative 2-[<sup>18</sup>F]fluoro-2-deoxy-D-glucose (2-[<sup>18</sup>F]FDG) is still the most used radiotracer for positron emission tomography, as it visualizes glucose utilization and energy demand. In general, 2-[<sup>18</sup>F]FDG is said to be t...
Main Authors: | Eva-Maria Klebermass, Mahshid Mahmudi, Barbara Katharina Geist, Verena Pichler, Chrysoula Vraka, Theresa Balber, Anne Miller, Arvand Haschemi, Helmut Viernstein, Nataliya Rohr-Udilova, Marcus Hacker, Markus Mitterhauser |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-09-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8247/14/9/910 |
Similar Items
-
The Additional Value of <sup>18</sup>F-FDG PET and MRI in Patients with Glioma: A Review of the Literature from 2015 to 2020
by: Natale Quartuccio, et al.
Published: (2020-05-01) -
The Relationship between Brown Adipose Tissue Activity and Neoplastic Status: an <sup>18</sup>F-FDG PET/CT Study in the Tropics
by: Huang Yung-Cheng, et al.
Published: (2011-12-01) -
Clinical Utility of <sup>18</sup>F-FDG PET in Neuroendocrine Tumors Prior to Peptide Receptor Radionuclide Therapy: A Systematic Review and Meta-Analysis
by: Emmanouil Alevroudis, et al.
Published: (2021-04-01) -
A phase II study for metabolic <it>in vivo </it>response monitoring with sequential <sup>18</sup>FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer: the Heidelberg REMOTUX trial
by: Berger Anne, et al.
Published: (2012-03-01) -
Can the Efficacy of [<sup>18</sup>F]FDG-PET/CT in Clinical Oncology Be Enhanced by Screening Biomolecular Profiles?
by: Hazel O’Neill, et al.
Published: (2019-01-01)